Breast Cancer Trial, Recruiting NCT06291896 Sponsor: Umbria Bioengineering Technologies Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT06291896
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women aged between 45 and 74 years old.
  • Women who have no symptoms or signs of breast cancer.
  • Women who are considered at average risk for breast cancer — meaning no known BRCA1, BRCA2, or TP53 gene mutations, and no previous history of breast cancer.
  • Women who have had a standard mammogram (either a traditional 2D mammogram or a 3D tomosynthesis scan, covering both breasts) within the past month with results available, or who have one planned for the same day as the MammoWave test or shortly after.
  • Women who are willing to follow the study procedures and recommendations.
  • Women who have signed a consent form before taking part in any study activity.

Who may not be able to join:

  • Women who have breast implants or prostheses.
  • Women who have symptoms or signs of suspected breast cancer.
  • Women with known BRCA1, BRCA2, or TP53 gene mutations, or who have previously had breast cancer.
  • Women who are pregnant.
  • Women whose breast cancer is known to show no signs in the breast itself — for example, where a tumour is only detectable through the armpit (confirm with trial site).
  • Women whose breast size is larger than the largest available cup size for the MammoWave device.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 0039 3490564302

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Umbria Bioengineering Technologies
Registry
ClinicalTrials.gov
Start date
15 March 2024
Est. completion
30 June 2026

Where this trial is recruiting

🇮🇹 Italy 🇵🇱 Poland 🇵🇹 Portugal 🇪🇸 Spain 🇨🇭 Switzerland

Primary endpoints

MammoWave® sensitivity; MammoWave® specificity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov